---
title: "Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease"
description: "Palvella Therapeutics, Inc. is advancing a Phase 3 clinical study titled ‘SELVA’ to evaluate the safety and efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel for treating microcystic lymphatic malformat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262951167.md"
published_at: "2025-10-27T19:15:42.000Z"
---

# Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease

> Palvella Therapeutics, Inc. is advancing a Phase 3 clinical study titled ‘SELVA’ to evaluate the safety and efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel for treating microcystic lymphatic malformations. The study involves approximately 40 participants and aims to assess treatment effects over 24 weeks. It began on January 16, 2024, with primary completion expected in 2025. Positive results could influence Palvella's stock performance and attract investor interest, especially with FDA involvement. Competitors in the rare disease sector are also monitoring the study's progress.

Palvella Therapeutics, Inc. is conducting a Phase 3 clinical study titled ‘SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations.’ The study aims to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants, with the option for extended treatment.

The intervention being tested is QTORIN 3.9% Rapamycin Anhydrous Gel, a drug designed to treat microcystic lymphatic malformations by evaluating its safety and efficacy over a 24-week period.

The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. This straightforward design aims to provide clear insights into the drug’s effectiveness.

The study began on January 16, 2024, with its primary completion anticipated in 2025. The most recent update was submitted on July 22, 2025, indicating ongoing recruitment and progress.

This study could significantly impact Palvella Therapeutics’ stock performance and investor sentiment, particularly if the results are positive, given the involvement of the FDA Office of Orphan Products Development. Competitors in the rare disease treatment space will be closely monitoring these developments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.

### Related Stocks

- [PVLA.US - Palvella Therapeutics](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 緬因州疾病控制與預防中心報告稱，緬因州已確認新增 4 例麻疹病例 | 緬因州疾病控制中心報告緬因州新增 4 例麻疹確診病例 | [Link](https://longbridge.com/en/news/276164223.md) |
| 癌症與血液疾病中心為德克薩斯州患者革新了 CAR-T 癌症治療的提供方式 | 癌症與血液疾病中心已啓動一項計劃，在德克薩斯州的社區醫療機構提供 CAR-T 療法，顯著擴大患者對這一先進癌症治療的獲取。該中心與當地醫院合作，正在治療首位患者，一名 62 歲的 B 細胞淋巴瘤男性患者。此項舉措是在德克薩斯州通過 3057 | [Link](https://longbridge.com/en/news/276139832.md) |
| UroGen 製藥的 CEO 讚揚 ZUSDURI 的上市勢頭、J-Code 的推動作用以及超過十億美元的峯值銷售目標 | Urogen Pharma 的首席執行官 Liz Barrett 強調了公司對尿路上皮癌的關注以及新膀胱癌療法 ZUSDURI 的商業推出。在最近的一次討論中，她指出 ZUSDURI 針對的是一大羣低級別中等風險非肌肉侵襲性膀胱癌（NMIB | [Link](https://longbridge.com/en/news/276020468.md) |
| 定期牙科檢查如何促進佛羅里達州維羅海灘的口腔健康 | 定期的牙科檢查對維護口腔健康和預防嚴重的醫療問題至關重要。它們通過去除牙菌斑來預防蛀牙，及早發現牙齦疾病，並監測口腔健康隨時間的變化。牙醫還可以識別其他健康問題的跡象，例如睡眠呼吸暫停或癌症。在佛羅里達州維羅海灘的常規檢查支持主動的口腔護理 | [Link](https://longbridge.com/en/news/276145403.md) |
| 在全球疼痛市場中，新機制和新模式存在顯著的機會 | 全球疼痛市場為創新提供了重大機會，特別是在開發非成癮性替代阿片類藥物方面。目前，全球批准的疼痛藥物中有 98% 是仿製藥，治療選擇缺乏多樣性。Vertex Pharmaceuticals 的 Journavx 最近獲得批准，標誌着一個突破， | [Link](https://longbridge.com/en/news/275921122.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
